Home / Health / Lilly's Foundayo Trails Wegovy in Early Sales
Lilly's Foundayo Trails Wegovy in Early Sales
8 May
Summary
- Foundayo's initial U.S. prescriptions were 7,335 in its fourth week.
- Analysts suggest Foundayo needs 22,000 weekly prescriptions for sales targets.
- Novo Nordisk's Wegovy has a first-mover advantage in the oral drug market.
Eli Lilly's new oral weight-loss medication, Foundayo, recorded 7,335 prescriptions in the United States during its fourth week of availability. This figure represents a more cautious initial uptake when contrasted with Novo Nordisk's Wegovy, which holds a first-mover advantage in the oral weight-loss drug market. Analysts observe that investors are increasingly focusing on the long-term potential of next-generation weight-loss pills rather than solely on early prescription numbers.
To achieve consensus expectations of $160 million in second-quarter sales, Foundayo's weekly prescription rate needs to significantly increase, with analysts estimating around 22,000 prescriptions per week. Lilly has indicated that over 8,000 prescribers are offering Foundayo, with a notable portion being new to prescribing oral GLP-1 medications. Despite the slower start, the market for these drugs is anticipated to grow substantially, potentially reaching millions of patients.
